| Literature DB >> 29767387 |
Peter Muris1,2,3, Dorien Roodenrijs4, Lut Kelgtermans4, Sonja Sliwinski4, Ulrike Berlage4, Hanna Baillieux4, Anne Deckers5,4, Marieke Gunther4, Bertien Paanakker4, Ida Holterman5,4.
Abstract
In this naturalistic clinical study, we explored the applicability and clinical effectiveness of Cogmed WMT, pharmacotherapy, and their combination for clinically referred children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Ninety youth with ADHD (ages 6-16 years) and their parents were offered the possibility to choose one of the three interventions. The motives for choosing various interventions were quite different. Medication was chosen because this treatment was expected to be most effective, but also because the Cogmed WMT program was regarded as too taxing. The choice for Cogmed WMT was mainly negatively motivated: participants tended to be strongly against the use of medication, found it a too rigorous step, or feared side effects and addiction problems. The choice for the combination treatment was strongly positively motivated: parents and youth indicated that they wanted to receive the best possible intervention and part of them also had high expectations of Cogmed WMT. In terms of clinical effectiveness, pharmacotherapy with stimulant medication and the combination treatment produced larger reductions in ADHD symptomatology than Cogmed WMT. Further, results indicated that Cogmed WMT selectively enhanced working memory performance. Finally, after conducting Cogmed WMT, youths and parents were more 'open' to accept pharmacotherapy as intervention, probably because the training increased greater insight in and awareness of the problematic features of ADHD.Entities:
Keywords: Attention-deficit/hyperactivity disorder; Clinical effectiveness; Cogmed working memory training; Naturalistic clinical study; Stimulant medication; Treatment preferences
Mesh:
Substances:
Year: 2018 PMID: 29767387 PMCID: PMC6208996 DOI: 10.1007/s10578-018-0812-x
Source DB: PubMed Journal: Child Psychiatry Hum Dev ISSN: 0009-398X
Demographic characteristics of the 90 youth participating in the present study
| Percentage, | |
|---|---|
| Gender (boys/girls) | |
| Boys | 64.4 |
| Girls | 35.6 |
| Age (months) | 129.59 (30.21) |
| 6–12 years | 71.1 |
| 13–16 years | 28.9 |
| Intelligence (IQ)a | 103.13 (15.75) |
| Education | |
| Regular primary school | 65.5 |
| Special primary school | 3.3 |
| Lower vocational education | 8.9 |
| Higher general secondary education | 7.8 |
| Pre-university education | 2.2 |
| Special secondary school | 1.1 |
| International school | 1.1 |
| Nationality of parents | |
| Dutch | 77.8 |
| Other | 22.2 |
| Family structure | |
| Complete | 65.4 |
| Broken | 34.6 |
| Socio-economic status | |
| Low | 45.7 |
| Medium | 38.3 |
| High | 16.0 |
| ADHD diagnosis | |
| ADHD combined type | 55.4 |
| ADHD predominantly inattentive type | 44.5 |
| ADHD-NOS | 1.1 |
| Level of interference (ADIS) | 1.1 |
| Comorbidity | |
| Yes | 61.7 |
| No | 38.3 |
| Comorbid disordersb | |
| Parent–child relational problem | 25 |
| Pervasive developmental disorder | 9 |
| Relational problem related to a mental disorder | 9 |
| Dyslexia | 7 |
| ODD/disruptive behavior disorder NOS | 7 |
| Anxiety/mood disorder | 6 |
| Identity problem | 5 |
| Reactive attachment disorder | 2 |
| Sibling relational problem | 2 |
| Partner relational problem | 1 |
| Adjustment disorder | 1 |
| Enuresis | 1 |
ADIS anxiety disorder interview schedule, ADHD section
aOnly available for 55 participants
bSome youth had more than one comorbid diagnosis
Fig. 1Flowchart of participants during various stages of this clinical study
Means scores (standard errors) on pre- and post-treatment questionnaires of youth in the three treatment conditions and main results of the repeated measures ANOVA (intent-to-treat analysis)
| Pre | Post |
|
| |||||
|---|---|---|---|---|---|---|---|---|
| Cogmed WMT | Stimulant medication | Combined treatment | Cogmed WMT | Stimulant medication | Combined treatment | |||
| ADHD-Q P total | 36.21 (2.45)a | 45.07 (2.51)b | 42.48 (2.70)b | 29.46 (2.52)c | 26.79 (2.69)c | 27.96 (2.89)c | 80.22*** | 5.77** |
| ADHD-Q P inattention | 13.94 (0.93)a | 16.86 (0.99)b | 15.04 (1.07)ab | 11.27 (1.05)c | 10.10 (1.12)c | 10.68 (1.20)c | 55.96*** | 4.00* |
| ADHD-Q P hyperactivity | 12.36 (1.01)a | 14.97 (1.08)a | 15.52 (1.16)a | 9.85 (0.94)b | 8.93 (1.01)b | 10.16 (1.08)b | 75.92*** | 4.46* |
| ADHD-Q P impulsivity | 9.88 (0.97)a | 13.38 (1.03)b | 11.92 (1.11)ab | 8.33 (0.88)c | 7.83 (0.94)c | 7.12 (1.01)c | 50.31*** | 5.25** |
| ADHD-Q T total | 38.09 (2.58)a | 38.52 (2.75)a | 37.24 (2.96)a | 33.46 (2.31)b | 18.17 (2.64)c | 15.92 (2.65)c | 99.87*** | 13.09*** |
| ADHD-Q T inattention | 13.58 (0.89)a | 13.31 (0.95)a | 14.08 (1.02)a | 11.52 (0.91)b | 6.90 (0.98)c | 7.04 (1.05)c | 79.74*** | 7.75** |
| ADHD-Q T hyperactivity | 12.82 (1.05)a | 14.00 (1.12)a | 12.20 (1.21)a | 12.49 (0.86)a | 6.17 (0.92)b | 4.88 (0.99)b | 71.13*** | 16.84*** |
| ADHD-Q T impulsivity | 11.70 (1.05)a | 11.21 (1.12)a | 10.96 (1.21)a | 9.46 (0.82)b | 5.07 (0.87)c | 4.00 (0.94)c | 77.55*** | 6.62** |
| ADHD-Q C total | 30.85 (2.51)a | 38.48 (2.68)b | 37.24 (2.88)ab | 26.06 (2.37)c | 23.62 (2.53)c | 27.60 (2.72)c | 39.64*** | 3.79* |
| ADHD-Q C inattention | 10.61 (0.96)a | 13.79 (1.03)b | 13.40 (1.11)b | 9.24 (0.91)ac | 8.66 (0.97)c | 9.84 (1.04)c | 25.92*** | 2.99 |
| ADHD-Q C hyperactivity | 11.91 (0.93)a | 14.72 (0.99)b | 14.32 (1.07)b | 10.61 (0.96)a | 8.93 (1.02)ac | 10.84 (1.10)ac | 32.97*** | 4.81* |
| ADHD-Q C impulsivity | 8.36 (0.99)a | 10.00 (1.06)a | 9.56 (1.14)a | 6.42 (0.81)b | 6.03 (0.86)b | 6.52 (0.93)b | 29.37*** | 1.23 |
| SDQ P HI problems | 6.91 (0.35)a | 8.24 (0.38)b | 8.04 (0.40)b | 6.18 (0.37)ac | 5.79 (0.40)c | 6.36 (0.43)c | 48.32*** | 4.95** |
| SDQ T HI problems | 7.82 (0.40)a | 8.07 (0.43)a | 7.68 (0.46)a | 7.27 (0.38)a | 4.21 (0.41)b | 4.08 (0.44)b | 92.84*** | 15.94*** |
| SDQ C HI problems | 6.24 (0.34)a | 7.38 (0.37)b | 7.36 (0.39)b | 5.42 (0.43)c | 4.14 (0.46)d | 5.20 (0.49)cd | 64.93*** | 8.04** |
| SDQ P impact | 2.24 (0.33)a | 3.28 (0.36)ab | 3.48 (0.38)b | 1.61 (0.31)ac | 0.93 (0.33)c | 1.52 (0.35)c | 41.54*** | 4.45* |
| SDQ T impact | 1.91 (0.21)a | 1.90 (0.22)a | 1.96 (0.24)a | 1.61 (0.19)a | 0.52 (0.20)b | 0.64 (0.22)b | 77.50*** | 10.17*** |
| SDQ C impact | 1.00 (0.27)a | 2.21 (0.29)b | 2.00 (0.31)b | 0.61 (0.23)c | 0.62 (0.25)c | 1.16 (0.26)c | 21.23*** | 3.10 |
| SDQ P other problems | 5.73 (0.75)a | 7.97 (0.79)b | 7.44 (0.86)ab | 5.12 (0.72)ab | 6.72 (0.77)b | 6.84 (0.83)b | 4.13* | 0.28 |
| SDQ T other problems | 7.70 (0.81)a | 6.66 (0.86)a | 7.04 (0.93)a | 6.27 (0.70)b | 4.17 (0.75)b | 4.64 (0.80)b | 29.66*** | 0.84 |
| SDQ C other problems | 7.85 (0.75)a | 8.48 (0.80)a | 7.96 (0.86)a | 6.94 (0.71)ab | 6.21 (0.76)b | 6.84 (0.81)b | 11.69** | 1.06 |
| BRIEF P total | 144.49 (3.70)a | 159.66 (3.94)b | 156.92 (4.25)b | 135.24 (4.16)c | 141.07 (4.43)c | 139.32 (4.78)c | 38.01*** | 1.57 |
| BRIEF P behavior regulation | 48.15 (1.95)a | 53.66 (2.08)a | 53.40 (2.24)a | 45.82 (1.80)ab | 49.97 (1.93)b | 47.20 (2.07)b | 16.48*** | 1.24 |
| BRIEF P metacognition | 96.06 (2.41)a | 106.14 (2.57)b | 103.12 (2.77)b | 89.15 (2.98)c | 91.17 (3.18)c | 91.92 (3.43)c | 48.68*** | 2.35 |
| BRIEF P working memory | 25.03 (0.62)a | 26.72 (0.66)a | 25.48 (0.71)a | 22.48 (0.81)b | 22.14 (0.86)b | 22.04 (0.92)b | 61.39*** | 1.85 |
WMT working memory training, ADHD-Q ADHD-Questionnaire, SDQ Strengths and Difficulties Questionnaire, HI hyperactivity-inattention, BRIEF behavior rating inventory of executive functioning, P parent, T teacher, C child
Superscripts pertain to between-group (Cogmed WMT vs. stimulant medication vs. combined treatment on both assessment occasions separately) and within-group (pre- to post-treatment) differences; means not sharing similar superscripts differ at p < .05; ***p < .001; **p < .01; *p < .05
Fig. 2Pre- to post-treatment effect sizes in the three treatment conditions calculated for the ADHD-Q total score as obtained from parents, teachers, and youth themselves. A Intent-to-treat analysis and B completer analysis. WMT working memory training, ADHD-Q ADHD-Questionnaire
Means scores (standard errors) on pre- and post-treatment questionnaires of youth in the three treatment conditions and main results of the repeated measures ANOVA (completer analysis)
| Pre | Post |
|
| |||||
|---|---|---|---|---|---|---|---|---|
| Cogmed WMT | Stimulant medication | Combined treatment | Cogmed WMT | Stimulant medication | Combined treatment | |||
| ADHD-Q P total | 34.96 (2.44)a | 44.83 (2.36)b | 41.90 (2.89)ab | 28.00 (2.60)c | 24.93 (2.52)c | 28.15 (3.08)c | 71.75*** | 6.28** |
| ADHD-Q P inattention | 13.96 (0.99)a | 16.07 (0.95)a | 15.20 (1.17)a | 11.00 (1.07)b | 9.17 (1.03)b | 10.55 (1.27)b | 51.20*** | 3.27* |
| ADHD-Q P hyperactivity | 11.82 (1.09)a | 15.47 (1.06)b | 15.15 (1.30)ab | 9.04 (0.99)c | 8.70 (0.96)c | 10.30 (1.17)c | 67.97*** | 4.48* |
| ADHD-Q P impulsivity | 9.14 (0.99)a | 13.42 (0.96)b | 11.55 (1.18)ab | 7.96 (0.93)ac | 7.13 (0.90)c | 7.30 (1.10)c | 42.69*** | 7.07** |
| ADHD-Q T total | 38.36 (2.76)a | 37.67 (2.67)a | 38.60 (3.26)a | 33.68 (2.42)b | 15.90 (2.34)c | 16.15 (2.86)c | 95.40*** | 12.86*** |
| ADHD-Q T inattention | 13.64 (0.97)a | 12.73 (0.94)a | 14.45 (1.15)a | 11.43 (0.95)b | 6.03 (0.91)c | 6.65 (1.12)c | 78.85*** | 7.56** |
| ADHD-Q T hyperactivity | 12.89 (1.09)a | 13.93 (1.06)a | 12.65 (1.29)a | 12.75 (0.88)a | 5.47 (0.85)b | 5.25 (1.05)b | 64.39*** | 16.94*** |
| ADHD-Q T impulsivity | 11.82 (1.14)a | 11.00 (1.10)a | 11.50 (1.34)a | 9.50 (0.87)b | 4.40 (0.84)c | 4.25 (1.03)c | 72.93*** | 6.22** |
| ADHD-Q C total | 30.32 (2.70)a | 35.87 (2.61)a | 38.35 (3.20)a | 24.82 (2.46)b | 21.70 (2.37)b | 27.95 (2.91)b | 33.79*** | 2.43 |
| ADHD-Q C inattention | 10.68 (1.02)a | 12.47 (0.99)ab | 14.20 (1.21)b | 8.93 (0.94)ac | 7.77 (0.91)c | 9.95 (1.11)c | 24.95*** | 1.82 |
| ADHD-Q C hyperactivity | 11.68 (1.03)a | 14.43 (0.99)a | 14.00 (1.21)a | 10.04 (1.03)ab | 8.83 (0.99)b | 10.55 (1.22)b | 27.09*** | 3.21* |
| ADHD-Q C impulsivity | 8.00 (1.05)a | 9.00 (0.98)a | 10.20 (1.24)a | 6.11 (0.83)ac | 5.10 (0.84)ac | 6.95 (0.98)c | 25.77*** | 1.12 |
| SDQ P HI problems | 6.79 (0.38)a | 8.30 (0.37)b | 8.05 (0.45)b | 6.07 (0.41)ac | 5.60 (0.39)c | 6.50 (0.48)c | 44.49*** | 6.20** |
| SDQ T HI problems | 7.71 (0.43)a | 8.03 (0.41)a | 7.85 (0.50)a | 7.18 (0.40)a | 3.97 (0.39)b | 4.05 (0.48)b | 86.19*** | 15.36*** |
| SDQ C HI problems | 6.04 (0.38)a | 7.27 (0.37)b | 7.35 (0.45)b | 5.11 (0.46)c | 3.90 (0.44)c | 5.15 (0.54)c | 59.32*** | 7.21** |
| SDQ P impact | 2.04 (0.36)a | 3.73 (0.35)b | 2.95 (0.42)ab | 1.50 (0.32)ac | 0.93 (0.31)c | 1.30 (0.38)c | 38.35*** | 6.82** |
| SDQ T impact | 1.89 (0.22)a | 2.07 (0.22)a | 1.75 (0.26)a | 1.57 (0.19)a | 0.50 (0.18)b | 0.45 (0.22)b | 78.40*** | 11.08*** |
| SDQ C impact | 0.93 (0.30)a | 2.17 (0.29)b | 1.85 (0.36)ab | 0.46 (0.23)c | 0.60 (0.22)c | 0.90 (0.27)c | 21.26*** | 2.52 |
| SDQ P other problems | 5.46 (0.79)a | 8.87 (0.76)b | 6.40 (0.93)a | 4.89 (0.74)a | 7.40 (0.72)b | 5.90 (0.88)ab | 3.80 | 0.56 |
| SDQ T other problems | 7.29 (0.81)a | 7.63 (0.79)a | 6.05 (0.96)a | 5.82 (0.70)b | 4.40 (0.67)b | 3.90 (0.82)b | 34.88*** | 2.04 |
| SDQ C other problems | 7.39 (0.79)a | 8.83 (0.76)a | 7.85 (0.93)a | 6.75 (0.79)ab | 6.47 (0.76)b | 6.65 (0.93)b | 10.34** | 1.51 |
| BRIEF P total | 143.50 (3.80)a | 162.53 (3.67)b | 152.80 (4.50)ab | 133.11 (4.39)c | 139.47 (4.24)c | 137.25 (5.20)c | 39.06*** | 2.28 |
| BRIEF P behavior regulation | 47.36 (2.05)a | 55.77 (1.98)b | 51.35 (2.42)ab | 45.04 (1.95)ac | 45.36 (2.05)c | 46.00 (2.31)c | 15.83*** | 0.97 |
| BRIEF P metacognition | 95.82 (2.50)a | 106.57 (2.42)b | 101.45 (2.96)ab | 87.75 (3.14)c | 89.33 (3.03)c | 91.25 (3.71)c | 50.20*** | 3.12 |
| BRIEF P working memory | 25.25 (0.63)a | 26.67 (0.61)a | 25.20 (0.75)a | 22.29 (0.86)b | 21.33 (0.83)b | 22.10 (1.02)b | 67.11*** | 3.04 |
Superscripts pertain to between-group (Cogmed WMT vs. stimulant medication vs. combined treatment on both assessment occasions separately) and within-group (pre- to post-treatment) differences; means not sharing similar superscripts differ at p < .05. ***p < .001; **p < .01; *p < .05
WMT working memory training, ADHD-Q ADHD-Questionnaire, SDQ Strengths and Difficulties Questionnaire, HI hyperactivity-inattention, BRIEF behavior rating inventory of executive functioning, P parent, T teacher, C child
Means scores (standard errors) on pre- and post-treatment performance-based tests of youth in the three treatment conditions and main results of the repeated measures ANCOVAA (intent-to-treat analysis)
| Pre | Post |
|
| |||||
|---|---|---|---|---|---|---|---|---|
| Cogmed WMT | Stimulant medication | Combined treatment | Cogmed WMT | Stimulant medication | Combined treatment | |||
| WISC digit span | 12.42 (0.44)a | 11.17 (0.46)a | 12.25 (0.49)a | 13.79 (0.51)b | 11.62 (0.53)ab | 13.64 (0.57)b | 3.99* | 1.59 |
| Corsi block-tapping | 13.87 (0.41)a | 12.93 (0.43)a | 13.37 (0.46)a | 16.70 (0.53)b | 13.93 (0.56)c | 16.88 (0.60)b | 7.16** | 6.32** |
| Stroop interference | 63.46 (6.85)a | 85.60 (7.13)a | 73.22 (7.68)a | 57.90 (4.37)b | 54.10 (4.55)b | 51.38 (4.90)b | 23.51*** | 4.78* |
| Bourdon-vos speed | 17.25 (0.73)a | 17.78 (0.77)a | 17.39 (0.82)a | 15.06 (0.51)b | 14.49 (0.53)b | 14.91 (0.57)b | 35.61*** | 1.54 |
| Bourdon-vos regularity | 3.76 (0.31)a | 3.66 (0.33)a | 3.20 (0.35)a | 2.64 (0.18)b | 2.28 (0.18)b | 2.16 (0.20)b | 24.15*** | 0.39 |
| Bourdon-vos accuracy | 22.49 (3.84)a | 20.62 (4.00)a | 22.20 (4.31)a | 15.93 (2.99)b | 12.64 (3.12)b | 10.42 (3.35)b | 4.85* | 1.04 |
| TEA-Ch sky search—selective attention | 4.53 (0.21)a | 4.24 (0.22)a | 4.32 (0.23)a | 3.68 (0.20)b | 3.35 (0.21)b | 3.35 (0.22)b | 11.98*** | 0.05 |
| TEA-Ch score!—sustained attention | 7.34 (0.36) | 6.94 (0.38) | 7.35 (0.41) | 7.96 (0.36) | 7.86 (0.37) | 7.86 (0.40) | 2.44 | 0.24 |
| TEA-Ch sky search DT—divided attention | 2.23 (0.90) | 2.86 (0.94) | 3.81 (1.01) | 1.67 (0.80) | 1.09 (0.84) | 3.00 (0.90) | 0.03 | 0.29 |
| TEA-Ch score! DT—divided attention | 14.31 (0.48)a | 13.55 (0.50)a | 14.28 (0.54)a | 15.15 (0.49)b | 15.88 (0.51)b | 15.46 (0.55)ab | 6.49* | 2.11 |
Superscripts pertain to between-group (Cogmed WMT vs. stimulant medication vs. combined treatment on both assessment occasions separately) and within-group (pre- to post-treatment) differences; means not sharing similar superscripts differ at p < .05
WMT working memory training, WISC Wechsler Intelligence Scale for Children, TEA-Ch test of everyday attention for children, DT dual task
***p < .001; **p < .01; *p < .05
AAll analyses were controlled for age
Means scores (standard errors) on pre- and post-treatment performance-based tests of youth in the three treatment conditions and main results of the repeated measures ANCOVAA (completer analysis)
| Pre | Post |
|
| |||||
|---|---|---|---|---|---|---|---|---|
| Cogmed WMT | Stimulant medication | Combined treatment | Cogmed WMT | Stimulant medication | Combined treatment | |||
| WISC digit span | 12.25 (0.49)a | 11.56 (0.46)a | 11.92 (0.56)a | 13.65 (0.56)b | 11.84 (0.53)a | 13.83 (0.65)b | 3.75* | 3.48* |
| Corsi block span | 13.86 (0.46)a | 12.79 (0.44)a | 13.50 (0.53)a | 17.11 (0.57)b | 14.13 (0.54)c | 17.35 (0.66)b | 6.40* | 6.04** |
| Stroop interference | 68.68 (7.27)a | 87.58 (6.89)a | 71.18 (8.44)a | 59.93 (4.90)b | 54.07 (4.64)b | 52.06 (5.69)b | 26.92*** | 4.21* |
| Bourdon-vos speed | 17.20 (0.82)a | 18.35 (0.78)a | 16.78 (0.95)a | 14.80 (0.56)b | 14.75 (0.53)b | 14.77 (0.65)b | 28.66*** | 2.95 |
| Bourdon-vos regularity | 3.76 (0.35)a | 3.71 (0.33)a | 3.22 (0.40)a | 2.57 (0.19)b | 2.25 (0.18)b | 2.08 (0.22)b | 19.21*** | 0.16 |
| Bourdon-vos accuracy | 22.84 (4.20)a | 20.00 (3.98)a | 26.13 (4.88)a | 15.22 (3.25)b | 12.95 (3.08)b | 11.27 (3.78)b | 4.92* | 2.19 |
| TEA-Ch sky search—selective attention | 4.52 (0.23)a | 4.30 (0.22)a | 4.34 (0.27)a | 3.52 (0.21)b | 3.41 (0.20)b | 3.35 (0.25)b | 12.46** | 0.07 |
| TEA-Ch score!—sustained attention | 7.38 (0.41) | 7.02 (0.39) | 7.25 (0.48) | 8.10 (0.38) | 7.81 (0.36) | 8.09 (0.44) | 3.40 | 0.01 |
| TEA-Ch sky search DT—divided attention | 2.38 (1.01) | 2.79 (0.95) | 3.90 (1.17) | 1.91 (0.92) | 2.12 (0.87) | 1.83 (1.07) | 0.05 | 0.39 |
| TEA-Ch score! DT—divided attention | 14.18 (0.53)a | 13.68 (0.50)a | 14.23 (0.61)a | 15.19 (0.54)b | 15.83 (0.51)b | 15.39 (0.62)ab | 7.23** | 1.22 |
Superscripts pertain to between-group (Cogmed WMT vs. stimulant medication vs. combined treatment on both assessment occasions separately) and within-group (pre- to post-treatment) differences; means not sharing similar superscripts differ at p < .05
WMT working memory training, WISC Wechsler Intelligence Scale for Children, TEA-Ch test of everyday attention for children, DT dual task
*** p < .001, ** p < .01, * p < .05, † p = .05
AAll analyses were controlled for age
Percentages of youth in each of the three treatment groups for whom the intervention was evaluated as positiveA on the post-treatment SDQ and the follow-up interview
| Cogmed WMT ( | Stimulant medication ( | Combined treatment ( | χ2(2) | |
|---|---|---|---|---|
| Post-treatment | ||||
| SDQ P reduced ADHD symptoms | 14.3a | 50.0b | 35.0ab | 8.35* |
| SDQ T reduced ADHD symptoms | 3.6a | 66.7b | 55.0b | 26.00*** |
| SDQ C reduced ADHD symptoms | 21.4a | 60.0b | 60.0b | 10.75** |
| SDQ P made problem more bearable | 35.7a | 80.0b | 55.0ab | 11.72** |
| SDQ T made problem more bearable | 17.9a | 60.0b | 60.0b | 12.89** |
| SDQ C made problem more bearable | 57.1 | 76.7 | 65.0 | 2.52 |
| One-year follow-up interview (P) | ||||
| Improved ADHD symptoms/daily functioning | 7.1a | 53.3b | 65.0b | 20.07*** |
| Helpfulness of intervention | 10.7a | 76.7b | 90.0b | 37.96*** |
Percentages not sharing similar superscripts differ at p < .05
WMT working memory training, SDQ Strengths and Difficulties Questionnaire, P parent, T teacher, C child
AAll variables were dichotomized so that chi square tests could be conducted without violating the ‘frequencies should be greater than 5’ assumption